Wall Street is positive on Adverum Biotechnologies Inc (ADVM). On average, analysts give ADVM a Buy rating. The average price target is $3, which means analysts expect the stock to rise by 188.46% over the next twelve months. That average ranking earns ADVM an Analyst Rating of 21, which is better than 21% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating ADVM a Buy today. Find out what this means to you and get the rest of the rankings on ADVM!